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ABSTRACT
Caffeine has been propoited to increase endurance exercise time to exhaustion. 
However, the effects of caffeine on high-intensity, intermittent exercise to exhaustion 
have not been widely studied. Therefore, the purpose of this study was to examine the 
effect o f  caffeine on intermittent, high intensity exercise to exhaustion in individuals with 
minimal daily dietary caffeine consumption. Seven male participants, age 26 ± 2  years, 
body mass 77 ± 11 kg, and 47 ± 7 ml/kg/miru performed a high-intensity exercise
bout under both caffeine and placebo conditions administered in a counterbalanced, 
double blind fashion. Participants cycled at 120% of peak power output for 60 seconds 
followed by 120 seconds o f recovery at 50 Watts. Work/rest cycles continued until 
voluntary exhaustion. Blood samples were taken immediately prior to administering 
caffeine or placebo beverages, one hour post absorption, and immediately following the 
conclusion of the exercise test No significant difference in time to exhaustion was found 
between caffeine and placebo trials (12.5 ±  5.9 vs 12.3 ± 6.6 min), nor did peak blood 
lactate concentration differ between trials (11.3 ± l.O vs 11.6 ± 1.9 mM). These results 
suggest that caffeine treatment provides no significant improvement in performance time 
during intermittent, high-intensity exercise to exhaustion.
Ill
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CHAPTER I
INTRODUCTION
Caffeine is the most widely used psychoactive drug in the world (James, 1991). 
The most common form o f caffeine consumption is coffee, which accounts for 
approximately 54% of caffeine ingestion, with tea accounting for approximately 43%.
The remaining 3% of caffeine ingestion is in the form o f chocolate or cocoa products, soft 
drinks, and medications (Gilbert, 1984). Because caffeine is virtually free of barriers to 
diffusion, it produces many effects including restlessness, increased lipolysis resulting in 
a proported glycogen sparing effect, alterations in neuromuscular transmission and 
mental acuity. Physiological and psychological alterations in behavior derived from 
caffeine consumption, have led to its use by athletes in an attempt to enhance 
performance.
While some studies have reported ergogenic benefits from consuming caffeine 
(Costill, 1978; Jackman et al., 1996, Trice & Hymes, 1995), other studies fail to show 
caffeine related ergogenic benefits (Cadarette et al., 1983, Williams, 1988).
To date, much o f the research concerned with the potential ergogenic benefits of 
caffeine has focused on endurance rather than short term exercise. Endurance athletes, 
such as triathletes and marathon runners, may find caffeine appealing because it is 
reported to alter substrate utilization (Costill et al., 1978; Spriet et al., 1992). Less clear
I
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2is the potential benefit for short term higher intensity activities where caffeine may act to 
modify neuromuscular transmission. Research findings in each of these areas have been 
inconsistent, with some studies reporting significant benefits while others show 
negligible differences between caffeine and control groups (Costill et al., 1992; Powers et 
al., 1983).
Currently, very little research has focused on the effects o f caffeine on 
performance involving short, intense bouts of exercise, separated by brief periods o f rest. 
It is possible that participants in sports such as hockey, tennis, and soccer may derive 
benefits fi-om caffeine supplementation prior to competition. These benefits may include 
performing at a higher intensity for a longer period of time due to a decrease in the 
perception of fatigue, elevated catecholamine levels, or enhanced neuromuscular 
transmission. This study proposes to research the effects of caffeine on short term, high- 
intensity exercise in an effort to further define the role of caffeine in improving 
performance.
Limitations
1. Participants for this study were college age males o f average physical characteristics 
and physical fitness level. Inference o f data to the population should be done with 
caution.
Assumptions
1. Participants gave a maximal effort during the peak aerobic capacity pretest, and both 
exercise test protocols.
2. Participants abstained fitjm all caffeine intake for a minimum of 4 days prior to the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3beginning of the exercise test and maintained this behavior until the conclusion o f the 
test
3. Participants performed a 12 hour abstinence of food prior to performing the exercise 
tests.
4. Peak caffeine levels occur one hour post absorption on an empty stomach.
Statement o f Hypotheses
Null Hypothesis:
Hg: Caffeine will not enhance performance and extend the time to exhaustion during 
exercise that is intermittent and o f high intensity.
Alternate Hypothesis:
H,: Caffeine will extend the time to exhaustion during intermittent, high-intensity 
exercise.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2
LITERATURE REVIEW 
Pharmacology
Caffeine is part o f the family methylated xanthines whose structure is based on 
the purine ring. Caffeine’s structure is represented by 1,3,7-trimethylxanthine and it’s 
most active isomers are theobromine (3,7-dimethylxanthine), theophylline 
(1,3-dimethyIxanthine), and paraxanthine (1,7-dimethybcanthine). Caffeine, theobromine 
and theophylline are naturally occurring products while paraxanthine is not.
Theophylline appears to convert reversibly between caffeine and theophylline isomers 
(Looser et al., 1974; Roberts & Waller, 1979) while theobromine and paraxanthine are 
products o f caffeine metabolism (Amaud, 1987). Xanthines are relatively insoluble in 
liquids. However, salt compound formation tends to improve xanthine solubility (Powers 
& Dodd, 1985).
The pharmacokinetics of caffeine are unique. Caffeine is virtually free of barriers 
to diffusion including the blood-brain barrier (Rail, 1985; Somani, Khana, & Bada,
1980). Plasma caffeine levels begin to increase within 15 minutes after an oral dose, with 
peak levels occurring within one to two hours depending on such factors as stomach 
contents and whether the caffeine was consumed during an activity or at rest (Axelrod & 
Reichenthal, 1953; Rail, 1980). The rate of caffeine excretion is a function of liver
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5metabolism. The half life o f caffeine generally ranges from two to four hours, although 
infants and individuals with hepatic abnormalities or impairment tend to show an 
increased caffeine half life. Other factors affecting caffeine half life include age, gender, 
smoking, and oral contraceptive use (Blanchard & Sawers, 1983; Callahan, Robertson, 
Branfinan, McComish, & Yesair, 1983; Yesair, Branfinan, & Callahan, 1984; Parsons & 
Neims, 1978).
An integral component o f the pharmacokinetics o f caffeine is dose size. The 
effectiveness o f caffeine as an ergogenic aid appears to be largely affected by the size of 
the caffeine dose administered. Graham and Spriet (1995) administered doses o f 3,6, 
and 9 mg per kilogram body weight to participants who ran at 85% VO,max until 
voluntary exhaustion. Endurance was significantly improved over the placebo trial with 
the 3 and 6 mg/kg doses but not with the 9 mg/kg dose, suggesting that athletes 
attempting to gain performance enhancement via caffeine supplementation need to avoid 
taking an excessively large dose. The International Olympic Committee has established a 
maximum acceptable urinary caffeine level of 12 jj-g/ml. Generally, a 9 mg/kg dose will 
not exceed this limit (Graham & Spriet, 1991; Van Soeren, Sathasivam, Spriet, &
Graham, 1993). A lethal dose of caffeine ranges between 40 and 50 mg/kg but may be 
lower if  other drugs are being taken concurrently. It appears that a dose between 3-6 
mg/kg provides the optimal balance between performance enhancement and side effects 
which include jitters, gastrointestinal discomfort, and an inhibition in the ability to 
perform meticulous movements (Spriet, 1995).
While part o f the effectiveness o f caffeine as an ergogenic aide is based on 
caffeine dose size, a second factor is the relative amount o f caffeine consumed daily. The 
question to be considered is whether minimal dietary caffeine supplementation is
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6ergogenically more effective than habitual caffeine use. Most studies agree that habitual 
caffeine use tends to impair the catecholamine response (Van Soeren et al., 1993; 
Robertson, Wade, Worionan, Woosley, & Oates, 1981). Van Soeren et al. (1993) studied 
the effects o f caffeine in naive and habitual caffeine users. Their results indicated that 
caffeine naive users showed a significant increase in epinephrine levels after consuming a 
5 mg/kg caffeine dose and exercising on a cycle ergometer, while caffeine habituated 
participants showed no such increase in epinephrine levels. Robertson et al. (1981) 
controlled the diet of eighteen participants for fourteen days. Participants were randomly 
assigned to one of two groups. Group I received a placebo beverage with each meal 
while Group H received a placebo beverage with each meal during days one through three 
and ten through fourteen with caffeine beverages being consumed during days four 
through ten. Group II plasma epinephrine and norepinephrine levels were significantly 
elevated on day four but returned to baseline levels within four days, while the plasma 
catecholamine levels did not significantly change in the control group.
With respect to short term high intensity exercise, there are three main effector 
sites for caffeine in the human body, the central nervous system, the neuromuscular 
junction, and the muscle contractile process (Williams, 1991). Each has been implicated 
in the observed benefits o f caffeine. Caffeine has pronounced effects on the central 
nervous system including reduced sleep, reduced reaction time, enhanced mental 
sharpness and neuromuscular transmission. The mechanism by which caffeine produces 
these results is unclear. Two hypotheses have been offered to explain the central nervous 
system effects. These are cyclic AMP accumulation through phosphodiesterase 
inhibition and competitive adenosine receptor blockade.
Indirectly, caffeine has been shown to promote cAMP accumulation (Sutherland
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7& Rail, 1958). Cyclic AMP mediates the actions o f many neurotransmitters and 
hormones in the central nervous system (Sutherland, Robison, & Butcher, 1968), while 
the enzyme phosphodiesterase mediates cAMP breakdown (Choi, Shamim, Padgett, & 
Daly, 1988). Blocking phosphodiesterase will result in cAMP accumulation, prolonging 
cAMP function, thus promoting the actions of neurotransmitters and hormones in the 
central nervous system. However, the plasma caffeine levels required to initiate this 
response are estimated to be 300;/g/ml which is well in excess of acceptable doses for 
humans (Fredholm 1985).
The second hypothesis proposed to explain the effects o f caffeine on the central 
nervous system is a competitive adenosine receptor blockade. Adenosine is a nucleotide 
which inhibits neurotransmitter release. Caffeine appears to compete with adenosine for 
xanthine-sensitive adenosine receptors (Williams, 1987). There are two different 
adenosine receptor types, a high affinity receptor, A l, and a low affinity receptor, A2 
(van Calker, Muller, & Hamprecht, 1979). The high affinity receptor has been shown to 
suppress physiological functions while the low affinity receptor has the opposite effect 
(Dunwiddie, 1985). As caffeine blocks both Al and A2 adenosine receptors, 
neurotransmitter turnover is improved. The dosage required to achieve measurable 
changes in receptor binding is well within the limits o f human consumption. Rail (1980) 
found that competitive adenosine receptor binding was possible with plasma caffeine 
concentrations ranging fi’om 5 to 30/zM. Furthermore, caffeine's virtual lack o f barriers 
makes it accessible to the unique xanthine-sensitive adenosine receptors located 
throughout the body. While adenosine receptor blockade accounts for the majority o f 
caffeine's major effects, other mechanisms are suspected of playing important, but less 
remarkable, roles such as stimulation, calcium release and diminished calcium reuptake
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
by the sarcoplasmic reticulum. (Amaud 1987).
Side Effects
While caffeine’s primary physiological mode o f action has not been established, 
several o f  side effects have been noted. These range from sleepless nights and heightened 
anxiety to quicker reflexes, heightened mental sharpness, and improved neuromuscular
transmission.
Reduced Sleep
Caffeine, through central nervous system stimulation, has a dramatic effect on 
sleep and sleep depravation. It has been suggested that caffeine’s largest central nervous 
system effect in adults is on sleep (Dews, 1982). Numerous studies have found that 
caffeine produces a delay in sleep onset, a reduction in sleep time, increased body 
movements during sleep and an increase in the number o f spontaneous awakenings 
(Muller-Limmroth cited in Battig, 1985; MuUin, 1933; Brezinova, 1975). People most 
susceptible to sleep disruption tend to be caffeine non-users or caffeine naive individuals. 
One study did not find an extended time to sleep onset (Nicholson & Stone, 1980). 
However, this was attributed to the dose being administered immediately prior to sleep 
which did not allow for adequate caffeine absorption to achieve peak plasma levels.
Reaction Time
Another aspect o f central nervous system stimulation which has been extensively 
studied is reaction time. Faster reaction times have been reported (Rapoport, Jensvold, 
Elkins, Buchsbaum, Wiengartner, Ludlow, Zahn, Berg, & Neims, 1981; Jacobson & 
Edgley, 1987; Roache & Griffiths, 1987) with caffeine ingestion. Overall the results are
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9often contradictory and generally lacking in consistency. Much o f the variability in 
results may be due to differences in the caffeine doses administered. Horst and Jenkins 
(1935) found that a 3 mg/kg dose resulted in consistently reduced reaction times while a 2 
mg/kg dose resulted in inconsistent reductions in reaction time. Additionally, large doses 
o f caffeine may provide no benefits at all. Jacobson and Edgley (1987) performed a 
study in which 300 mg caffeine, 600 mg caffeine or placebo were administered. 
Participants were situated in a chair with a bright light positioned directly in fi’ont o f the 
chair. Additionally, participants placed the palm o f their hand on a breaker switch 
located 60 degrees fix>m horizontal on their right side. The reaction time test was initiated 
when the bright light was turned on and concluded when participants removed their hand 
off the breaker switch. A significant improvement in reaction time was found with the 
300 mg dose while no improvements were found in the placebo or the 600 mg dose. 
Roache and Griffiths (1987) also tested reaction time with 200,400, and 600 mg doses o f  
caffeine. A computerized reaction time task required the participants to distinguish 
between randomly selected even and odd numbers ranging fi’om 1 to 8. In response to the 
odd or even number, participants pressed a left or right telegraphing key, respectively. 
Trials began with the presentation o f a randomly selected digit and terminated when 
either key was depressed. The time interval between trials varied fi-om 0.5 seconds to 5 
seconds apart. Test results indicated a significant reduction in reaction time with the 400 
mg dose but no significant change in reaction time with the 200 or 600 mg dose. These 
results suggest that an optimal dose o f caffeine for improving reaction time is between 
300 and 400 mg depending on the body mass of the individual.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Mental Sharpness
Mental sharpness is defined as the ability to maintain focus on a task over a 
prolonged length o f time. Caffeine has a distinct effect on this fimction of the central 
nervous system. It is believed that caffeine benefits mental sharpness by delaying the 
onset o f metal fatigue, evidenced by a study performed by Fagen, Swift, and Tiplady 
(1988) in which participants were administered a 200 mg dose prior to performing 
prescribed tasks for one hour. The largest improvements in performance were found in 
the second half of the one hour test. However, the theory o f delayed onset of mental 
fatigue has been contested by Battig and Buzzi (1986) who presented the task stimulus at 
a varied rate which participants could control, rather than at a fixed rate. For each correct 
response the interval between stimuli was decreased, and for each incorrect response the 
interval between stimuli was increased. The purpose o f this study was to determine 
whether delayed onset of fatigue was truly responsible for improved mental sharpness.
By adjusting the interval between task stimuli, processing rate rather than error rate, 
could be measured with respect to performance. Processing rate increased with increased 
caffeine doses of 150 and 450 mg over each ten minute segment of the testing session. 
These
results provide evidence that improvements in mental performance are due to more than a 
delay in mental fatigue.
Neuromuscular Transmission 
Caffeine has been shown to enhance neuromuscular transmission (Brekenridge, 
Bum, & Matshinsky, 1967; Hofinaim, 1969; Wilson, 1973). Eke-Okoro (1982) studied 
reflex action in the lower leg in the presence o f several variables including caffeine. The 
procedure was to electrically induce dorsiflexion and the subsequent plantar reflex was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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measured in participants who had consumed an average o f 125 milligrams o f caffeine. 
Results o f this study showed that the stimulus threshold was reduced and the muscle 
afferent and efferent amplitudes were enlarged one hour after caffeine ingestion. 
Brekenridge et al. (1967) proposed that increased muscular cyclic AMP is responsible for 
the enhanced rate of neuromuscular transmission. However, this theory was discounted 
when it was learned that caffeine’s effects are directed toward the presynaptic neuron 
(Goldberg & Singer, 1969; Hofinann, 1969). In particular, elevated levels of 
neurotransmitter release were found. Apparently, caffeine increases the quantity of 
neurotransmitter released per stimulus, while the speed o f the transmission is not affected 
by caffeine.
Free Fatty Acid Release
Recently, Graham and Spriet (1991) have shown that caffeine significantly 
increases catecholamine levels in the blood. Specifically, their results showed a rise in 
plasma epinephrine levels after consuming 6 mg/kg or more of caffeine. The effects of 
increased levels of epinephrine include increased free fatty acid release, increased heart 
rate, vasoconstriction, suppressed visceral muscle activity, and bronchiole dilation 
(Marieb, 1992). Each o f these may be beneficial during exercise. However, the most 
notable o f these effects is enhanced firee fatty acid release because o f a purported 
glycogen sparing effect (Chesley, Hultman, & Spriet, 1994; Graham & Spriet, 1991).
Increased plasma free fatty acid levels promote an accumulation of cAMP 
activating lipoprotein lipase and breaking down triglycerides into glycerol and free fatty 
acids. The advantage of an elevated free fatty acid level is a metabolic shift toward 
increased lipid oxidation which, in turn, reduces the demand for glucose and glycogen. 
Glycogen sparing in this manner, would allow the athlete to exercise at a higher
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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percentage o f maximal capacity for a longer period o f time. Glycogen sparing through 
lipid oxidation has been shown to occur during the first 15 to 20 minutes o f exercise at 
80% o f maximal aerobic capacity (VO^max) (Spriet, MacLean, Dyck, Hultman, 
Cederblad, & Graham, 1992). Spriet et al. (1992) performed a study with the dual 
purpose o f examining the chronology o f glycogen use during exercise in addition to 
identifying possible mechanisms for this glycogen sparing. Participants cycled to 
exhaustion at 80% VO^max one hour after ingesting 9mg/kg caffeine. Muscle biopsies 
were taken prior to the beginning o f exercise, at the 15 minute mark, and at the 
completion of exercise. Results indicated a significant increase in the time to exhaustion 
between caffeine (96.2 ±  8.8 min) and placebo (75.8 ± 4.8 min). Furthermore, glycogen 
use was significantly reduced in the first 15 minutes of exercise during the caffeine vs. 
placebo trial (4.7 ±1.5 vs. 10.6 ±1.3 mmol-kg dry muscle '-minute '). The prolonged time 
to exhaustion during the caffeine exercise bout conformed with the length o f time in 
which glycogen sparing occurred.
Several studies have shown a glycogen sparing effect of increasing fi-ee fatty acids 
(Essig, Costill, & VanHandel, 1980; Erickson, Schwarzkopf, & McKenzie, 1987; Spriet 
et al., 1992; Graham, Rush, & van Soeren, 1994), while others have not (Tamopolsky, 
Atkinson, MacDougall, Sale, & Sutton, 1989; Toner, Kiikendall, Delio, Chase, Cleary, & 
Fox, 1982; Ravussin, Bogardus, Scheidegger, LaGrange, Horton, & Horton, 1986). 
Typically, the respiratory exchange ratio (RER) has been used to estimate the changes 
seen in ftiel metabolism with caffeine consumption. However, two separate studies 
analyzed caffeine induced metabolic shifts directly via post-exercise muscle biopsy 
(Essig et al., 1980; Erickson et al., 1987). During 30 minutes of exercise at 69%VO,max 
, Essig et al. (1980) found a 42% reduction in muscle glycogen use following ingestion of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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5 mg/kg caffeine. Similarly, Erickson et al. (1987) found a 30% reduction in muscle 
glycogen use after 90 minutes o f exercise at 65 to 70%VO2max with a caffeine dose of 5 
mg/kg body weight. The results o f these studies suggest that increased uptake of free 
fatty acids in the muscle may suppress the need for glycolysis or glycogenolysis. 
Increased lipid oxidation results in an increase in citrate concentration. Citrate inhibits 
phosphofructokinase (PFK) which limits the conversion o f fructose-6-phosphate to 
fructose 1,6-bisphosphate, a rate limiting step in glycolysis. The result is a glycogen 
sparing effect through accumulation of glucose-6-phosphate.
The validity of glycogen sparing induced by elevated plasma epinephrine and the 
resultant increase in free fatty acid levels has been questioned in recent years. Two 
studies performed by Van Soeren (1993, 1996) have indicated that elevated epinephrine 
levels have no significant impact on RER or free fatty acid levels. In the first study, Van 
Soeren et al. (1993) examined the metabolic and catecholamine responses to caffeine in 
both caffeine users and non-users. Non-users performed two exercise bouts after 
consuming either 5mg/kg caffeine or placebo. Exercise bouts were completed on a cycle 
ergometer at 50% of maximal oxygen consumption and lasted for one hour. Caffeine 
users performed three exercise bouts designed to control for caffeine use. The first test, 
under placebo conditions, occurred after four days o f  voluntary caffeine abstinence. Over 
the next fourteen days, participants were given a 5mg/kg caffeine dose in two parts or a 
placebo. The second and third exercise tests occurred at seven day intervals and were 
similar to the exercise tests of the caffeine non-users. The results indicated that, despite 
significantly elevated epinephrine levels, non-users failed to show a decrease in RER or 
increase in free fatty acid concentration. Caffeine users were found to have elevated 
epinephrine levels during exercise under placebo conditions. However, caffeine users
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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also failed to show a change in free fatty acid concentration or RER. Because 
epinephrine stimulates glycogenolysis, it is possible that any benefits gained fix>m 
glycogen sparing via elevated plasma fiue fatty acid levels would be neutralized. In the 
second study. Van Soeren, Mohr, Kjaer, and Graham (1996) tested six tetraplegics and 
two paraplegics to determine whether caffeine directly stimulated tissues or acted 
indirectly via increased epinephrine levels induced by caffeine. Subjects were given 
either a placebo or 6 mg/kg o f caffeine. Epinephrine levels in the tétraplégie were not 
significantly elevated during the caffeine trial while plasma free fatty acid levels were 
elevated. Conversely, paraplegics showed a significant increase in epinephrine, similar to 
what would be expected from resting able-bodied individuals, and an increase in plasma 
free fatty acids. These results indicate that increased free fatty acid levels are not 
dependent on elevated epinephrine levels, and instead suggest that caffeine directly 
effects adipose tissues.
The concept that caffeine results in glycogen sparing has two potential limitations. 
First, glycogen sparing has only been shown to benefit endurance athletics engaging in 
aerobic exercise. High intensity exercise requires energy production which may exceed 
the oxidative capacity preventing the maximization o f the potential advantages presented 
by elevated plasma free fatty acid levels. In fact, there may not even be a glycogen 
sparing effect in high intensity exercise. Jackman, Wendling, Friars, and Graham, (1996) 
studied the effects of caffeine on high intensity exercise. Fourteen participants ingested 
a 6mg/kg caffeine dose and cycled at 100% of maximal oxygen capacity three times, 
separated by six minutes of rest. The first two exercise bouts were two minutes in 
duration at a controlled power output. The third exercise bout continued to exhaustion. 
Jackman found that time to exhaustion was improved with caffeine compared with
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placebo. Additionally, lactate production was higher during the caffeine trial. They 
concluded that the ergogenic benefit o f caffeine was not the result of glycogen sparing.
A second limitation of glycogen sparing by caffeine is related to dietary 
constraints imposed on the subject. It has been reported that diets high in carbohydrate 
negate any caffeine-induced, glycogen sparing effects (Weir, Noakes, Myburgh, & 
Adams, 1987; Giles & McLaren, 1984). Weir et al. (1987) tested six trained runners 
under conditions o f a high fat content meal alone, a high carbohydrate meal followed by 
caffeine ingestion, or a three day diet consisting o f high fat or high carbohydrate meals in 
combination with caffeine. Following a dose o f 6.5 mg/kg caffeine, participants 
exercised for 120 minutes at 75% o f maximum oxygen uptake. The result was that free 
fatty acid levels did not rise as anticipated after a high carbohydrate diet and high 
carbohydrate meal followed by caffeine ingestion. Similarly, Giles and McLaren (1984) 
exercised participants for 120 minutes on a treadmill at 75% maximum oxygen uptake 
one hour after ingesting a 5 mg/kg caffeine dose alone or in combination with glucose 
ingestion. They found a significant decrease in peak plasma free fatty acid levels with 
glucose and caffeine ingestion compared to caffeine alone. These results have 
implications for athletes who carbohydrate-load prior to competitive events such as a 
marathon or triathlon. However, other studies contradict these results and show that 
caffeine-induced performances are not affected by high carbohydrate diets (Spriet et al., 
1992). Spriet cycled eight subjects to exhaustion at 80% maximal oxygen uptake one 
hour after ingesting a 9 mg/kg caffeine dose or placebo. Each participant was instructed 
to consider the exercise as a hard workout in their weekly training program and to 
maintain diets similar to precompetition diets. Analysis of each subject’s diet showed an 
average of 59.6% carbohydrate content prior to testing. Despite consuming a high
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carbohydrate diet, participants cycled significantly longer in the caffeine trial than the 
placebo trial.
Although it is largely understood that elevated catecholamine levels promote 
elevated fi’ee fatty acid levels, the cause and effect relationship o f caffeine and elevated 
catecholamine levels is less clear. The effects o f caffeine on catecholamine secretion are 
confounded by studies ( Graham & Spriet, 1991; Spriet et al., 1992) that failed to show an 
increase in norepinephrine despite an increase in epinephrine, suggesting that the effects 
o f caffeine on catecholamine secretion are not affecting the sympathetic nervous system. 
Rather, caffeine appears to be acting on the adrenal medulla. A greater epinephrine 
response to caffeine has also been found during exercise (Kjaer, Bangsbo, Lortie, & 
Galbo, 1988), which was attributed to an increased rate o f secretion rather than a 
decreased rate o f epinephrine reabsorption.
While glycogen sparing may be the most significant ergogenic effect o f caffeine, 
other ergogenic benefits have been reported. Several studies report that VO,max is 
enhanced by caffeine consumption (Toner et al., 1982; Wiles, Bird, Hopkins, & Riley, 
1992). Toner et al. (1982) found a statistically significant increase in VO,max in 
subjects pedaling a cycle ergometer following caffeine ingestion relative to a control 
group. Wiles et al. found performance improvements in 1500 meter run and “finishing 
burst” sprint times following the consumption o f caffeinated coffee. Additionally, eight 
o f the ten participants in this study recorded higher VO, values during the caffeine trial. 
Wiles et al. (1992) observed that the higher VO, levels were probably due to faster 
running speeds during the caffeine trial. However, the faster running speeds could also 
be attributed to a general decrease in the perception of fatigue, which could cause 
participants to select a higher speed. Conversely, research exists which fails to show an
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increase in VO^max with caffeine treatment (Powers, Byrd, Tuliey, & Callender, 1983; 
Dodd, Brooks, Powers, and TuU^, 1991). Powers et al. (1983) studied, seven 
participants who performed a graded exercise test on a cycle ergometer one hour after 
consuming 5 mg/kg o f  caffeine or placebo. Initial resistance was 30 Watts and was 
increased by 30 Watts every three minutes. No difference in maximal oxygen uptake or 
time to exhaustion was found between caffeine and placebo trials. Dodd et al. (1991) 
used a similar test protocol in which initial resistance began at 50 Watts and increased by 
30 Watts every two minutes. Nine caffeine habituated participants were compared with 
eight participants who abstained from caffeine consumption or were considered caffeine 
naive. Participants were given a placebo, 3 mg/kg, or 5 mg/kg caffeine one hour prior to 
beginning the test. While VO^max was significantly increased in caffeine naive 
participants, this only occurred after consuming 5 mg/kg caffeine. There was no 
significant difference in VO^max among caffeine habituated participants.
Caffeine and Skeletal Muscle 
Skeletal muscle appears to be the target organ for many o f caffeine’s purported 
ergogenic effects. Because caffeine almost completely equilibrates with total body water, 
the highest concentration o f  caffeine can probably be found in skeletal muscle (Burg, 
1975). It has been shown that type 1 and H skeletal muscle fibers have different levels o f 
sensitivity to caffeine. Deuster, Bockman, & Muldoon, (1985) studied muscle 
contractures induced by caffeine. Isolated strips of cat soleus muscle (100% type I fibers) 
and gracilis muscle (95% type H fibers) were incubated with doses of caffeine ranging 
from 0.25 to 16 mM. The results showed that type I muscle fibers were significantly 
more sensitive to caffeine than type H muscle fibers. This difference in sensitivity to 
caffeine between type I and type H muscle fibers was also found in human skeletal
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muscle by Mitsumoto, Deboer, Bunge, Andrish, Tetzlaff, and Cruse, (1990). Caffeine 
has been shown to stimulate calcium release from its storage site in the sarcoplasmic 
reticulum (Rail, 1985). This stored calcium can be subdivided into calcium-sensitive and 
inositol triphosphate-sensitive reservoirs. The action o f caffeine on calcium stores in the 
sarcoplasmic reticulum may be inconsequential, however, because the dose of caffeine 
required to elicit a  significant mobilization o f calcium is toxic in vivo (Fredholm 1985). 
While a caffeine dose o f 9 mg/kg body weight will produce an approximate plasma 
caffeine concentration o f 15 /zg/ml, it was determined that plasma caffeine concentrations 
of approximately 300 /Ug/ml would have to be achieved to see any significant results on 
sarcoplasmic reticulum calcium release. Alternately, Poledna and Morad (1983) 
suggested that caffeine, rather than stimulating calcium release, suppressed calcium 
reuptake into the sarcoplasmic reticulum which would also facilitate muscle contraction. 
However, the caffeine dose required to achieve this effect is again prohibitive in vivo.
In vitro studies performed on muscle tissue of individuals susceptible to malignant 
hyperthermia showed intensified muscle contractions after subjects consumed a caffeine 
load compared with muscle tissue from normal people (Britt, 1979; Britt, Endrenyi, Scott, 
& Frodis, 1980; Gronert, 1980). It was presumed that the intensified muscle contractions 
were due to an increased plasma calcium level in the malignant hyperthermia muscle.
The effects o f caffeine on muscle tension and maximal voluntary force have also 
been studied to determine any beneficial effects from caffeine. Williams (1987) tested 
hand grip strength under caffeine and placebo conditions and found no difference in force 
production between the two conditions. Conversely, it has been shown that caffeine 
increases maximal tension production of the adductor poUicis when electrically 
stimulated (Lopes, Aubier, Jardin, Aranda, & Macklem, 1983). While improvements
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were found at submaximal frequencies of stimulation (sSO Hz), no improvements 
occurred at stimulation frequencies above 50 Hz. Additionally, maximal voluntary 
contraction have shown no improvement Conversely, several studies have failed to show 
a significant effect of caffeine on tension or the maximal voluntary level of force 
produced during a muscle contraction (Bugyi, 1980; Lopes et al., 1983; Taraopolsky et 
al., 1989; Williams, 1987). It was theorized that increased motor unit recruitment might 
occur during submaximal contractions as evidenced by an increase in tension produced at 
submaximal electrical stimulation (Lopes et al., 1983). However, Williams (1987) 
measured handgrip strength after caffeine ingestion and found no increase in motor unit 
activation as determined by an electromyogram. Additionally, caffeine did not improve 
the motor unit recruitment to force production ratio with submaximal handgrip 
contractions.
Caffeine and Performance
The effects of caffeine supplementation on performance have been investigated in 
several competitive situations, primarily endurance events. In general caffeine appears to 
have a positive ergogenic effect on endurance exercise. Costill, Dalsky, and Fink (1978) 
examined the exercise performance o f nine competitive cyclists pedaling at 80% of 
VO^max. Participants ingested either 330 mg o f caffeinated coffee or decaffeinated 
coffee one hour prior to the onset o f exercise. Average time to exhaustion improved from 
75.5 minutes under placebo conditions to 90.2 minutes under caffeine conditions. Spriet 
et al. (1992) administered a 9 mg/kg caffeine dose to participants, one hour prior to 
cycling at 80% o f VO^max, and found a significant improvement in time to exhaustion 
during caffeine trials (96.2 ± 8.8 min) rather than placebo trials (75.8 ± 4.8 nun).
The effects of caffeine on short term exercise are not as clear. Collomp, Caillaud,
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Audran, Chanal, and Prefaut (1990) studied participants who cycled at 100% of their 
VOjmax until the required level o f woric could no longer be maintained. While 
participants work times were increased in the caffeine trial, the results were not 
significantly different fium the placebo trial. Wiles, et al. (1992), on the other hand, 
showed a statistically significant improvement in performance with caffeine. Participants 
ran a 1500 meter time trial on a treadmill. Each participant also had to complete the run 
with a one minute finishing burst under either caffeine or placebo conditions. In the 
caffeine trials, there was a decrease in the amount o f time needed to complete the 1500 
meter run, and a faster one minute finishing burst, both o f which were significantly 
different fi’om the control trial.
It is possible that the ergogenic effects o f caffeine may be related to the athletic 
level o f the participants. The ergogenic effect appears to be more prevalent when 
competitive or highly trained athletes are used as participants. For example, Collomp, 
Ahmaidi, Chatard, Audran, and Prefaut (1992) studied freestyle sprint performance in 
two distinct groups. The first group consisted of seven swimmers who had been training 
an average o f five times per week for at least four months, and had recently undergone 
sprint training in anticipation of a forthcoming swim meet. The second group consisted 
o f seven subjects who were former competitive swimmers, but who had not practiced 
consistently, though they were occasionally swimming. All o f the subjects were asked to 
abstain from any caffeinated drinks for one week prior to the test. Subjects were 
randomly given a gelatin capsule containing either 250 mg o f  caffeine or a placebo, and 
swam two 100-m sprints, separated by a twenty minute rest period. The time required to 
complete the 100-m sprint was significantly decreased in the trained subjects but not in 
the untrained subjects with caffeine. Collump also noted that while blood lactate
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concentrations were significantly increased in both the trained and untrained swimmers, 
the trained swimmers had a higher relative blood lactate content after each 100-m sprint 
regardless o f  whether caffeine or placebo was being used, possibly due to a decline in the 
perception o f  fatigue with caffeine in trained athletes.
In summary, caffeine has been reported to have three main effector sites, the 
central nervous system, the neuromuscular junction, and the muscles contractile 
machinery. Two hypotheses proposed to explain central nervous system stimulation 
include phosphodiesterase inhibition and competitive adenosine receptor blockade 
through caffeine consumption. Through caffeine’s effects on various physiological 
processes, a multitude o f  ergogenic benefits have been proposed, ranging fi-om a 
glycogen sparing effect to sharper mental acuity and quicker reaction time. Most of the 
research has focused on endurance events which are aerobic by nature with very little 
research targeting high-intensity intermittent exercise. Therefore, the purpose of my 
study is to examine the effects of caffeine on high-intensity intermittent cycle ergometery 
to exhaustion.
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CHAPTERS
METHODOLOGY
Subjects
Seven apparently healthy male participants volunteered for this study.
Participants were selected based on their diet which consisted of minimal to negligible 
amounts o f daily dietary caffeine. Daily caffeine intake was estimated to be less than 75 
mg per day. The mean physical attributes (and standard deviation) of the participants 
were: age in years = 26.00 (±1.83), body mass = 76.92 kg (±10.56), and peak V02 = 
46.99 ml/kg/min. (±7.37).
Pretest
One week prior to the onset of the study, participants performed a peak oxygen 
uptake test on a (Quinton cycle ergometer. Participants were connected to a Vista 
metabolic measurement system (Vacumed Inc., Ventura, CA) via a one way non­
rebreathing mask. Participants were also fitted with a Vantage heart rate monitor. After a 
5 minute warmup, participants began pedaling at 60 to 80 revolutions per minute, with 
initial resistance set at 50 Watts. Resistance was increased by 25 Watts every minute 
until peak oxygen consumption levels were determined. At the conclusion of the peak 
oxygen uptake test, a five minute warm down period followed. Following the pretest.
22
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participants were instructed to abstain from caffeinated products for the next two weeks.
Test Protocol
Upon arrival on a test day, participants’ body mass was determined, and a 50//1 
blood sample was drawn with two heparinized microtubules. Participants consumed a 
300 ml cup o f decaffeinated coffee containing either caffeine (6 mg/kg body weight) or 
placebo. After consuming the beverage, participants waited for one hour to allow for 
caffeine absorption. During this time, an explanation o f  the exercise protocol was given 
to participants with an opportunity to receive answers to any questions. Toward the end 
o f the absorption period, participants were seated on the cycle ergometer and outfitted 
with a Vantage heart rate monitor. Immediately prior to the beginning of the exercise 
protocol, a second 50^1 blood sample was drawn from each participant. The test protocol 
began with a five minute warmup at 50 Watts resistance followed by the test protocol 
sequence. Each sequence consisted of cycling for 60 seconds at 120% of the maximal 
power output achieved during the peak VO, pretest, with recovery periods o f cycling at 
50 Watts for 120 seconds. The sequence was computer programmed to generate accurate 
force load and interval duration. The exercise protocol was terminated when participants 
were unable to maintain a minimum of 60 revolutions per minute for 10 consecutive 
seconds, hnmediately following the conclusion of the test, a third 50//1 microtubule 
blood sample was drawn. A five minute warm down followed the end of the exercise 
test.
The participants were instructed to abstain from caffeine and report one week later 
for their second trial. Participants followed the same procedure as in the first trial, except 
participants received the opposite treatment to the first. The placebo and caffeine trials 
were administered to participants in a counterbalanced design. Following the second
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trial, participants were asked whether they could distinguish between the two 300 
milliliter beverages which they consumed, and which test protocol was more difficult.
Blood lactate levels were determined using a Yellow Springs Model 23L lactate 
analyzer (Yellow Springs Instruments, Yellow Springs, OH). Plasma caffeine levels 
were determined using a Gilford 260 spectrophotometer at a wavelength o f 273 
nanometers according to a modification o f the procedure of Axelrod and Reichenthal 
(1953), and Routh, Shane, Arredondo, and Paul (1969) (see Appendix HI). Further 
revisions were necessary to accommodate smaller blood samples than those required in 
the original procedure.
A double blind crossover design was implemented in this study to help control 
internal validity. Since this was a within subjects study, the statistical analysis used was 
a one way ANOVA with repeated measures for caffiene dose and paired t-Test for time to 
exhaustion, work stages completed, total power output, and lactate concentration.
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CHAPTER 4 
RESULTS
Plasma Caffeine Concentration 
In the caffeine trial, plasma caffeine levels were significantly elevated over 
baseline levels one hour after consuming caffeine (p<0.001) (Figure I). Baseline caffeine 
levels were 1.66 ± 0.2lAig/ml while post absorptive caffeine levels were 6.72 ±
1.40^g/ml. Baseline and one hour post-absorption caffeine levels during the placebo trial 
were 1.51 ± 0.22/^g/ml and 1.95 ± 0.30^g/ml respectively, and failed to reach 
significance (Figure 2).
Time to Exhaustion
Ingestion of 6 milligrams o f  caffeine per kilogram body weight one hour prior to 
intermittent cycling at 120% of peak power did not significantly increase exercise time 
over the placebo condition. The mean time to exhaustion during the caffeine trial was 
12.54 ± 5.86 minutes while the placebo condition yielded a mean time to exhaustion of 
12.31 ± 6.62 minutes (Figure 3). The difference in performance by woric stages failed to 
reach significance. The mean number o f work stages completed was 4.68 ± 1.94 and 4.59 
± 2.24 for caffeine and placebo trials respectively (Figure 4). The difference in total 
power output between caffeine and placebo trials was not significantly different (Figure
25
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5). The mean total power output for caffeine and placebo trials was 1661.61 ± 701.75 
Watts and 1630.38 ±  801.33 Watts respectively.
Blood Lactate Concentration 
Figure 6 indicates blood lactate concentration achieved during caffeine and 
placebo trials. Blood lactate concentration averaged 11.33 ± 1.04 mM and 11.63 ± 1.89 
mM during caffeine and placebo trials respectively and failed to reach significance.
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CHAPTERS
DISCUSSION
This study examined the effects of caffeine on healthy, active, college age males 
performing high-intensity, intermittent cycling. The primary finding of this study was 
that caffeine failed to significantly increase time to exhaustion over a placebo. Caffeine 
levels were significantly elevated during the caffeine trial compared with baseline levels. 
Additionally, plasma lactate levels were not significantly different between caffeine and 
placebo.
These findings differ firom those of Trice and Haymes (1995). They investigated 
the effects o f caffeine on high-intensity, intermittent exercise to exhaustion and found a 
significant increase in performance time o f 16.25 minutes during the caffeine trial in 
addition to a 20 minute increase in the range of time to exhaustion. The exercise protocol 
used by Trice and Haymes and the protocol adopted for this study were based on two 
previous studies performed by Astrand, Astrand, Christensen, and Hedman (1960,1960). 
Astrand et al. studied the effects of altering the length o f  work/rest periods while 
maintaining the work/rest ratio at I to 2 or I to 4. The total quantity of work to be 
performed within a 30 minute period was standardized to allow for direct comparisons 
between tests. Plasma lactic acid concentration was measured, while the same amount of 
work over a 30 minute period was maintained. Results indicated that a 60 second bout of
33
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high-intensity exercise followed by a 120 second recovery period yielded lactic acid 
values o f 142 mg per 100 ml, which was significantly higher than 60 seconds o f work 
followed by 120 seconds o f recovery which resulted in peak lactic acid values o f 114 mg 
per 100 ml. Based on these results, it was decided to adopt the 60 second work and 120 
second recovery workrrest ration for the current study. It was also decided that 
participants would cycle at 120% o f their maximal power output.
Trice and Haymes exercise protocol, which consisted of three 30 minute 
repetitions o f 60 second work and rest intervals at 85 to 90% of maximal power output 
resulted in plasma lactate levels o f 4.00 ± 0.70 and 4.24 ± 0.86 for caffeine and placebo 
trials respectively. The exercise protocol for the current study attained plasma lactate 
levels o f 11.33 ± 1.04 and 11.63 ± 1.89 for caffeine and placebo trials respectively. It is 
possible that Trice and Haymes found a significant improvement in time to exhaustion 
because participants reached a balance point between lactate production and removal. 
Additionally, if participants were cycling at 85% of V02max, recovery during the early 
stages of exercise might permit glycogen sparing through increased lipolysis. Previous 
studies have suggested that caffeine may inhibit lactate production via increased lipid 
oxidation resulting in a decrease in utilization o f glucose and glycogen (Chesley, 1994; 
Graham & Spriet, 1991). Such benefits have been reported to occur within the first 15 to 
20 minutes of exercise at 80% o f  maximal aerobic capacity (Spriet et al. 1992). This 
spared glycogen is then available for use in the later stages o f exercise, extending the time 
to exhaustion. Trice and Haymes reported an increase in the time to exhaustion o f 16.25 
minutes. In the current study, an equilibrium between lactate production and elimination 
was unlikely because of the higher intensity of work load was prohibitive. At 120% of 
maximal aerobic capacity, participants were exercising well above the lactate threshold
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making glycogen sparing unlikely.
It has been speculated that caffeine may be beneficial during anaerobic exercise. 
Collomp et al. (1992) compared a group of highly trained swimmers with occasional 
swimmers who were formerly highly trained. Each group performed two 100 meter 
fi-eestyle sprints separated by 20 minutes, under both caffeine and placebo conditions. 
Blood lactate levels were similar for both groups regardless of the caffeine or placebo 
condition. However, only the highly trained swimmers improved their sprint speed 
during both sprints. Collomp et al. speculated that specificity of training may be 
necessary to obtain any ergogenic benefits from caffeine during supramaximal exercise. 
While participants for the current study were active, none had specifically trained on a 
cycle ergometer for any length o f time under anaerobic conditions.
It is possible that the level of physical training may also be important in deriving 
ergogenic benefits from caffeine during short term, high intensity exercise. Highly 
trained athletes appear to draw greater benefits from caffeine than less well conditioned 
athletes (Collomp, Ahmaidi, Audran, Chanal, & Prefaut, 1991; Collomp et al., 1992; 
Wiles et al., 1992). Type I muscle fibers, which are highly oxidative, have been shown 
to be more sensitive to caffeine than type II fibers (Duester, 1985; Mitsumoto, et al.,
1990). One o f the adq)tations to aerobic exercise is an increase in oxidative capacity of 
muscle as evidenced by an increase in both size and number of mitochondria (Essig and 
White, 1981). While the participants for this study were active, they were not considered 
highly trained. Whether caffeine would provide an advantage to highly trained endurance 
athletes during intermittent high-intensity exercise remains to be determined.
A recent study suggested that the manner in which caffeine is administered might 
have an impact on the ergogenic benefits associated with caffeine. Graham, Hibbert, and
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Sathasivam (1995) reported that caffeine administered in tablet form may be more 
effective than regular coffee or caffeine dissolved in decaffeinated coffee. Participants 
performed 5 exercise tests in which they ran to exhaustion at 85% o f their V02max one 
hour after consuming either a caffeine or placebo capsule with water, or regular coffee, 
decaffeinated coffee or decaffeinated coffee with a caffeine supplement. The caffeine 
dose and volume o f liquid to be consumed were both standardized to eliminate any 
variability between tests. Graham et al. found no difference in time to exhaustion 
between the three beverages and placebo capsule. However, participants ran significantly 
longer after consuming caffeine in capsule form. Plasma epinephrine levels measured 
throughout the test indicated a significant increase between caffeine and placebo 
treatments, but no significant difference between caffeine treatments. It was postulated 
that caffeinated and decaffeinated coffee contain an additional element which negates the 
ergogenic benefits associated with caffeine.
In this study, caffeine was dissolved in a 300 mg cup of decaffeinated coffee. 
Following the conclusion of the last exercise test, six o f seven participants correctly 
identified which exercise test contained caffeinated beverages. Five of the participants 
felt jittery prior to beginning the caffeine trial exercise protocol and one participant 
experienced post-exercise gastric discomfort associated with the caffeine beverage. 
Despite experiencing characteristics associated with consuming large quantities o f 
caffeine, participants were unable to significantly improve time to exhaustion during the 
caffeine trial. This lends some validity to the belief that caffeine dissolved in 
decaffeinated coffee will increase levels of plasma epinephrine without providing any 
ergogenic benefits.
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CHAPTER 6 
CONCLUSIONS
Caffeine has been extensively studied in recent years in an attempt to capitalize on 
it’s potential ergogenic benefits. However, results are often inconsistent and 
contradictory, making an accurate assessment o f caffeine’s potential as an ergogenic aid a 
difficult task. This study focused on the effects o f caffeine during high-intensity, 
intermittent exercise to exhaustion. The results o f this study indicated that caffeine naive 
participants who consumed a large dose of caffeine one hour prior to undertaking a high- 
intensity, intermittent bout of exercise did not significantly improve the length o f time to 
exhaustion. Though a caffeine dose o f this magnitude will significantly elevate plasma 
caffeine levels, the level of exercise intensity appears to be too high to take advantage of 
the ergogenic benefits associated with caffeine during exercise of moderate intensity. 
Ergogenic benefits may be attainable at this level o f work if the participants are highly 
trained and target their training toward anaerobic cycling sprints. Results of future 
caffeine studies in this realm are anticipated to be variable depending on individual 
differences in age, daily caffeine ingestion, and fitness level.
37
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STATISTICAL RESULTS
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Table 1 : Plasma Caffeine Level - Caffeine Trial
Anova: Single Factor
Pre/Post Plasma Caffeine Level (ug/ml)
Caffeine Trial
SUMMARY
Groups Count Sum Average Variance
Pre-Treatment 7 11.653 1.665 0.045
Post Absorption 7 31.714 4.531 0.815
ANOVA
Source o f  Variation SS MS F P-value F  crit
Between Groups 28.747 1 28.747 66.805 3.02E-06 4.747
Within Groups 5.164 12 0.430
Total 33.911 13
Table 2: Plasma Caffeine Level - Placebo Trial
Anova: Single Factor
Pre/Post Plasma Caffeine Level (ug/ml)
Placebo Trial
SUMMARY
Groiqjs Count Sum Average Variance
Pre-Treatment 7 10.571 1.510 0.047
Post Absorption 7 12.199 1.743 0.069
ANOVA
Source o f  Variation SS d f MS F P-value F  crit
Between Groups 0.189 1 0.189 3.267 0.096 4.747
Within Groups 0.696 12 0.058
Total 0.885 13
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Table 3: Time to Exhaustion
t-Test: Paired Two Sample for Means 
Time to Exhaustion (minutes)
40
Caffeine Placebo
Mean 12.54 12.31
Variance 34.39 43.78
Observations 7.00 7.00
Pearson Correlation 0.97
Hypothesized Mean Difference 0.00
df 6.00
tStat 0-36
P(T<=t) one-tail 0.37
t Critical one-tail 1.94
P(T<=t) two-tail 0.73
t Critical two-tail 2.45
Table 4: Performance bv Work Stages
t-Test: Paired Two Sample for Means 
Woik Stages
Caffeine Placebo
Mean 4.68 4.59
Variance 3.75 5.01
Observations 7.00 7.00
Pearson Correlation 0.98
Hypothesized Mean Difference 0.00
df 6.00
t Stat 0.43
P(T<=t) one-tail 0.34
t Critical one-tail 1.94
P(T<=t) two-tail 0.68
t Critical two-tail 2.45
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Table 5: Total Power Output
t-Test: Paired Two Sample for Means 
Power Output (Watts)
41
Caffeine Placebo
Mean 1661.61 1630.38
Variance 492447.53 642127.62
Observations 7.00 7.00
Pearson Correlation 0.98
Hypothesized Mean Difference 0.00
df 6.00
tStat 0.44
P(T<=t) one-tail 0.34
t Critical one-tail 1.94
P(T<=t) two-tail 0.67
t Critical two-tail 2.45
Table 6: Plasma Lactate Concentration
t-Test: Paired Two Sample for Means
Plasma Lactate Concentration (mM)
Caffeine Placebo
Mean 11.33 11.63
Variance 1.08 3.55
Observations 6.00 6.00
Pearson Correlation 0.23
Hypothesized Mean Difference 0.00
df 5.00
tStat -0.38
P(T<=t) one-tail 0.36
t Critical one-tail 2.02
P(T<=t) two-tail 0.72
t Critical two-tail 2.57
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DATE: October 9, 1996
TO: James a. Herman (KIN)
M/S: 3034
FROM:  ^ Lawrence Golding
y*- Chairman, Biomedical Committee of the 
Institutional Review Board
RE : Status of Human Subject Protocol entitled:
"Effects of Caffeine on High-Intensity, Intermittent
Exercise to Exhaustion"
OS? #504sl096-090
This memorandum is official notification that the protocol for 
the project referenced above has been approved by the Biomedical 
Committee of the Institutional Review Board. This approval is 
approved for a period of one year from the date of this 
notification and work on the project may proceed.
Should the use of human subjects described in this protocol 
continue beyond a year from the date of this notification, it 
will be necessary to request an extension.
If you have any questions or require any assistance, please give 
us a call at 895-1357.
cc: Dr. J. Young (KIN-3034)
OSP File
Office of Sponsored Programs 
4505 Maryland Parkway •  Box 451037 • Las Vegas, Nevada 89154-1037 
(702) 895-1357 • FAX (702) 895-4242
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Consent Form for Participation in Research 
Exercise Physiology Laboratory 
University of Nevada, Las Vegas
Title:
The Effects of Caffeine on High-Intensity, Intermittent Exercise to Exhaustion 
Purpose:
Of all the central nervous system stimulants, caffeine is among the most widely used 
drugs in the world. Caffeine has been manipulated by athletes in an attempt to enhance 
their performance. Most o f the research surrounding the purported effects of caffeine 
have focused on caffeine’s influence during endurance exercise. To date, very little 
research has focused on high-intensity exercise to exhaustion. Therefore, the purpose of 
this study is to examine the effects of caffeine on high-intensity, intermittent exercise.
Procedures:
Participants will report to the exercise physiology lab at least one week prior to the 
beginning of the test protocol. At this time, peak oxygen uptake levels will be measured 
during an cycle ergometer exercise protocol. Prior to beginning the exercise protocol, a 
one way rebreathing valve will be fitted to the participant to measure respiratory gases. 
The warm up period o f the exercise protocol will consist o f the participant cycling for 5 
minutes with minimal resistance. At the conclusion of the warm up period, the 
participant will pedal with a resistance of 50 watts for one minute. An additional 25 watts 
of resistance will be added at the end of each one minute segment. This will continue 
until the participant can not maintain an adequate level o f work. Upon completion of the 
peak oxygen uptake test, participants will be asked to abstain fi'om all caffeine during the 
following two weeks in an attempt to obtain the strongest possible effect fiom the 
caffeine sample. Caffeine abstinence spanning two weeks is necessary to allow 
participants to perform the exercise protocol under caffeine and placebo conditions.
Participants will report to the exercise lab at their assigned time, following a 12 hour 
overnight fast. At this time, a small blood sample will be drawn fiom the finger into a 
microtubule. Participants will be given a caffeine solution based on body mass or a 
placebo and asked to sit for one hour. At the end o f  the one hour absorption period, a 
second blood sample will be drawn fiom the finger into a microtubule. Afier a 5 minute 
warm up period with minimal resistance, the test protocol will begin. Based on results 
obtained from the peak oxygen uptake test, the participant will be asked to cycle 80 
revolutions per minute for one minute at 120% of peak oxygen uptake. This period will 
be followed by a two minute rest period in which resistance will be reduced to 50 Watts. 
At the end of the two minute rest period, the same resistance will be placed on the cycle 
and the participant asked to cycle 80 revolutions per minute for one minute. These 
work/rest periods will continue until the participant is unable to maintain an adequate 
level of work consistent with the test parameters. At the end o f the test, a third
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micortubule blood sample will be drawn from the participant. A cool down period in 
which the participants cardiorespiratory condition will be closely monitored.
The following week will consist o f  the same procedure with the exception o f the caffeine 
or placebo sample. Participants will receive the alternate supplement during the second 
week.
Risks:
Due to the intense level of exercise required for this experiment, participants may 
experience some muscle fatigue during the test protocol. Delayed onset muscle soreness 
may also develop within 48 hours following the exercise protocol. Abrupt cessation of 
caffeine consumption may result in some discomfort. Additionally, some gastrointestinal 
discomfort may result from consumption of caffeine or placebo solutions.
Benefitsi
There are two benefits associated with this experiment. First, the participant will receive 
an accurate appraisal of their peak oxygen uptake capacity (V02 max) based on the 
current state of physical conditioning. Second, the results o f this study will contribute to 
the knowledge and understanding of caffeine and its effect on athletic performance.
All information regarding this experiment will be held in the strictest of confidence.
Only those people directly involved with this experiment will be permitted access to this 
information. If this study is published in a scientific journal or presented at a conference, 
names and identities will be altered to protect the confidentiality of the participants.
Right to refuse or withdraw:
Participation in this study is voluntary. Participants may refuse to sign the consent form 
or withdraw from the experiment at any time.
Questions:
Any questions or concerns that may arise can be addressed by Jim Herman at 735-4242 
or John Young, Ph D. at 895-4626. Questions regarding participant’s rights during 
human subjects research can be answered by the UNLV Office of Sponsored Programs at 
895-1357.
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Please read the statement below, and sign and date this form if you agree with the 
conditions o f  the study.
I have read and understand this form and the content of the test procedure. 
Furthermore, I have volunteered for this study o f  my own volition. I understand the test 
protocol and all o f my questions have been answered to my satisfaction. I acknowledge 
that I may withdraw from the study at any time without recrimination.
Participant Name (print) Signature o f Participant Date
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CAFFEINE ASSAY
Principle:
The premise behind this method for caffeine extraction is based on caffeine’s ability to 
absorb light at 273 nanometers. Below is a list o f the reagents need to perform this assay. 
Also included is a list of instructions with values reduced for 25 microliter (pi) blood 
samples.
Reagents:
NaCl
0.1 Normal (N) NaOH
Benzene
5NHC1
Procédure:
1. Prepare each 2 ml capped ependorf tube with:
18.75 pg NaCl 
6.25 pi NaOH 
125 pi Benzene
2. Add 25 pi of serum to a prepared 1.5 ml ependorf tube.
3. Cap and mix by inversion and shake mechanically for 15 minutes.
4. Centrifuge tubes for 15 minutes (1000 x gravity).
5. Transfer 100 pi aliquot of the upper phase to a tube containing 50 pi o f  5 N HCl.
6. Cap tubes and shake mechanically for 5 minutes.
7. Suction the benzene layer from the contents o f the tube.
8. Transfer 37.5 to 40 pi of the aqueous phase to a quartz micro cuvette and read in a
spectrophotometer calibrated against a water blank at 273 nanometers.
9. Plot results on a regression line constructed from serial dilution samples of known
concentration (5 pg/ml to 20 pg/ml).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
49
Normal Values
Five milligrams o f  caffeine per kilogram body weight in 250 ml solution will 
result in plasma caffeine levels of 3.5 to 9.4 /zg/ml one hour later (Axelrod &
Reichenthal, 1953).
Reference:
Axelrod, J., & Reichenthal. J. (1953). The fate of caffeine in man and a method 
for its estimation in biological material. Journal of Pharmacology and Fxperimental 
Therapeutics, 107, 519-523.
Routh, J., Shane, N., Aredondo, E., & Paul, W. (1969). Determination o f caffeine 
in serum and urine. Clinical Chemistry, 15, 661-668.
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Participant 1
Age (years)...................................................27
Weight (kg) .................................................89
V02 (max-kg-BW)...................................... 43
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.66
Peak Caffeine (pg/ml)...........................4.09
Placebo Trial
Baseline Caffeine (pg/m l).....................1.72
Peak Caffeine (pg/ml)........................... 1.97
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 12.00
Placebo Trial ..................................... ........
Time to Exhaustion (minutes)
Caffeine Trial ..................................... 12.85
Placebo T ria l....................................... 12.60
Total Power Output (Watts)
Caffeine Trial .......................................1892
Placebo T ria l.........................................1794
Participant 2
Age (years)...................................................25
Weight (kg) .................................................65
V02 (m axkg'BW )...................................... 60
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.38
Peak Caffeine (pg/ml)...........................5.61
Placebo Trial
Baseline Caffeine (pg/m l).....................1.27
Peak Caffeine (pg/ml)........................... 1.35
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 10.30
Placebo Trial ..................................... 11.70
Time to Exhaustion (minutes)
Caffeine Trial .......................................6.75
Placebo T ria l.........................................6.88
Total Power Output (Watts)
Caffeine Trial .......................................1073
Placebo T ria l.......................................1124
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Participant 3
Age (years)...................................................25
Weight (kg) .................................................71
V 02 (m axkg'BW ).......................................45
Caffeine Trial
Baseline Caffeine (pg/m l)..................... 1.52
Peak Caffeine (pg/m l)...........................5.79
Placebo Trial
Baseline Caffeine (pg/m l).....................1.54
Peak Caffeine (pg/m l)........................... 1.79
Lactate Concentration (mM/L)
Caffeine Trial .....................................  12.60
Placebo Trial .....................................  10.60
Time to Exhaustion (minutes)
Caffeine Trial ....................................... 8.45
Placebo T ria l......................................... 6.77
Total Power Output (Watts)
Caffeine Trial .......................................1139
Placebo T ria l..........................................913
Age (years)...................................................29
W ei^ t (kg) .................................................78
V02 (max'kg'BW)...................................... 55
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.69
Peak Caffeine (pg/m l)...........................4.25
Placebo Trial
Baseline Caffeine (pg/m l).....................1.47
Peak Caffeine (pg/m l)...........................1.59
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 12.40
Placebo Trial .....................................  15.20
Time to Exhaustion (minutes)
Caffeine Trial ......................................24.63
Placebo T ria l....................................... 24.98
Total Power Output (Watts)
Caffeine Trial ...................................... 3108
Placebo T ria l........................................ 3234
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Participants
Age (years)................................................... 23
Weight (kg) ................................................. 72
V02 (m axkg'BW )...................................... 46
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.81
Peak Caffeine (pg/m l)...........................3.26
Placebo Trial
Baseline Caffeine (pg/m l).....................1.28
Peak Caffeine (pg/m l)........................... 1.60
Lactate Concentration (mM/L)
Caffeine Trial .....................................  10.30
Placebo Trial .....................................  11.40
Time to Exhaustion (minutes)
Caffeine Trial .....................................  12.93
Placebo T ria l.......................................  15.75
Total Power Output (Watts)
Caffeine Trial ....................................... 1628
Placebo T ria l......................................... 1898
Age (years)................................................... 25
W ei^t (kg) ................................................. 75
V02 (m axkg'BW )...................................... 42
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.56
Peak Caffeine (pg/m l).......................... 4.69
Placebo Trial
Baseline Caffeine (pg/m l).....................1.85
Peak Caffeine (pg/m l).......................... 2.15
Lactate Concentration (mM/L)
Caffeine Trial .....................................  10.70
Placebo Trial .....................................  11.20
Time to Exhaustion (minutes)
Caffeine Trial .....................................  12.70
Placebo T ria l.......................................  12.33
Total Power Output (Watts)
Caffeine Trial .......................................1551
Placebo T ria l......................................... 1430
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Participant 7
Age (years)....................................................27
Weight (kg) ..................................................94
V02 (max-kg-BW)....................................... 40
Caffeine Trial
Baseline Caffeine (pg/m l).................... 2.03
Peak Caffeine (pg/m l)...........................4.03
Placebo Trial
Baseline Caffeine (pg/m l).....................1.43
Peak Caffeine (pg/m l)........................... 1.75
Lactate Concentration (mM/L)
Caffeine Trial .....................................  11.70
Placebo Trial ........................................9.70
Time to Exhaustion (minutes)
Caffeine Trial ........................................9.45
Placebo T r ia l ..........................................6.83
Total Power Output (Watts)
Caffeine Trial ........................................1242
Placebo T r ia l ......................................... 1020
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
BIBLIOGRAPHY
Arnaud, M J. (1987). The pharmacology o f caffeine. Progress in Drug Research, 
I I ,  273-313.
Astrand, L, Astrand, P., Christensen, E., & Hedman, R. (I960). Intermittent 
muscular work. Acta Physiologica Scandinavica. 48,448-453.
Astrand, I., Astrand, P., Christensen, E., & Hedman, R. (1960). Myohemoglobin 
as an oxygen-store in man. Acta Physiologica Scandinavica. 48, 454-460.
Axelrod, J., & Reichenthal, J. (1953). The fate o f caffeine in man and a method 
for its estimation in biological material. Journal o f Pharmacology and Experimental 
Therapeutics, 107, 519-523.
Battig, K. (1985). The physiological effects o f coffee consumption. In MN 
Clifford, & KC Wilson (Eds.), Coffee: Botony, biochemistry and production o f beans and 
beverage (pp. 394-439). London: Croom-Helm.
Belief, S., Kershbaum A., & Finch E.M. (1968). Response of free fatty acids to 
coffee and caffeine. Metahnlism, 17,702-707.
Blanchard, J., & Sawers, S.J.A. (1983). Comparative pharmacokinetics o f caffeine 
in young and elderly men. Journal of Pharmacokinetics and Biopharmaceutics, 11, 109- 
126.
Breckenridge, B.M., Bum, J.H., & Matshinsky, F.M. (1967). Theophlline,
55
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
56
epinephrine and neostigmine facilitation on neuromuscular transmission. Eioceedings o f 
the National Academy of Sciences o f the United States of America, 57,1893-93.
Brezinova, V. (1975). Two types o f insomnia: Too much waking or not enough 
sleep. British Journal of Psychiatry, 126,439-445.
Britt, B.A., Endrenyi, L., Scott, E., & Frodis, W. (1980). Effect of temperature, 
time and fascicle size on the caffeine contracture test. Canadian Anaesthetists’ Society: 
Journal, 27, 1-11.
Bugyi, G.J. (1980). The effects o f moderate doses of caffeine on fatigue 
parameters o f the forearm flexor muscles. American Corrective Therapy Journal, 34,49- 
53.
Burg, A. (1975). Physiological disposition of caffeine. Drug Metabolism Review, 
4, 199-228.
Cadarette, B.S., Levine, L, Berube, C.L., Posner, B., & Evans, W. (1983). Effects 
of varied doses o f caffeine on endurance performance to fatigue. Biochemistry of 
Exercise, 13, 871-877.
Callahan, M.M., Robertson, R.S., Branfman, A.R., McComish, M.F., & Yesair, 
DW. (1983). Comparison of caffeine metabolism in three nonsmoking populations after 
oral administration o f radiolabelled caffeine. Drug Metabolism and Disposition, 11,211- 
217.
Chesley, A., Hultman, E., & Spriet, L.L. (1994). Variable effects o f caffeine on 
muscle glycogenolysis in recreationally active subjects during intense aerobic exercise. 
Canadian Journal o f Applied Physiology, 19. lOP (Abstract).
Choi, OJJ., Shamim, M.T., Padgett, W.L., & Daly, J.W. (1988). Caffeine and 
theophylline analogues: correlation of behavioral effects with activity as adenosine
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
57
receptor antagonists and as phosphodiesterase inhibitors. Life Sciences, 43,387-98.
CoUomp, K., Ahmaidi, S., Chatard, J.C., Audran, M„ & Prefaut, C. (1992). 
Benefits o f caffeine ingestion on sprint performance in trained and imtrained swimmers. 
European Journal Applied Physiology, 64, 377-380.
Collomp, K., Caillaud, C., Audran, M., Chanal, J.L., & Prefaut, C. (1990). 
Influence o f acute and chronic bouts o f caffeine on performance and catecholamines in 
the course of maximal exercise. Comptes Rendus des Seances. Société de Biologie et de
Costill, D.L., Coyle E., Dalsky G., Evans W., Fink W., & Hoopes D. (1977). 
Effects of elevated plasma FF A and insulin on muscle glycogen usage during exercise. 
Journal o f Applied Physiology, 43, 695-699.
Costill, D.L., Dalsky, G.P., & Fink, WJ. (1978). Effects of caffeine ingestion on 
metabolism and exercise performance. Medicine and Science in Sports and Exercise, 10, 
155-158.
Deuster, P.A., Bockman, E.L., & Muldoon, S.M. (1985). In vitro responses of 
skeletal muscle to halothane and caffeine. Journal o f Applied Physiology, 58, 521-527. 
Dews, P 3 ., (1982). Caffeine. Annual Review of Nutrition, 2, 323-341.
Dodd, S.L., Brooks E., Powers SiC., & Tulley R. (1991). The effects o f caffeine 
on graded exercise performance in caffeine naive versus habituated subjects. European 
Journal o f Applied Physiology, 62,424-429.
Dunwiddie, T.V. (1985).The physiological role o f adenosine in the central 
nervous system. Fntemational Review o f Neurobiology, 27, 63-139.
Eke-Okoro, S T. (1982). The H-reflex studied in the presence of alcohol, aspirin, 
caffeine, force and fatigue. Electromyography and Clinical Neurophysiology, 22, 579-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
58
89.
Erickson, MA., Schwarzkopf, R J., & McKenzie, RJD. (1987). Effects o f 
caffeine, fructose and glucose ingestion on muscle glycogen utilization during exercise. 
Medicine and Science In Sports and Exercise, 19,579-583.
Essig, D.A, Costill, D.L., & VanHandel, P J .  (1980). Effects o f caffeine ingestion 
on utilization o f muscle glycogen and lipid during leg ergometer cycling. International 
Journal o f  Sports Medicine, 1, 86-90.
Essig, D.A., & White, T.P. (1981). Effects o f caffeine on glycogen and 
triglyceride concentration in the soleus and plantaris muscles of the exercising rat.
Fagan, D., Swift, C.G., & Tiplady, B. (1988). Effects of caffeine on vigilance and 
other performance tests in normal subjects. Journal of Psychopharmacology, 2, 19-25.
Fisher S. M., McMurray R. G., Berry M., Mar M. H., & Forsythe W. A. (1986). 
Influence o f caffeine on exercise performance in habitual caffeine users. International 
Journal o f Sports Medicine, 7,276-280.
Fitts, R.H., & Holloszy, J.O. (1976). Lactate and contractile force in frog muscle 
during development of fatigue and recovery. American Journal o f Physiology, 231,430- 
433.
Flinn, S., Gregory J., McNaughton L.R., Tristan S., & Davies P. (1990). Caffeine 
ingestion prior to incremental cycling to exhaustion in recreational cyclists. International 
Journal o f Sports Medicine,! 1,188-193.
Fredholm, B.B. (1985). On the mechanism of action of theophylline and caffeine. 
Acta Medica Scandinavica, 217, 149-153.
Gilbert, R.M. (1976). Caffeine as a drug of abuse. In R. J. Gibbins, Y. Israel, H.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
59
Kalant, R.E. Popham, W. Schmidt, & R.G. Smart (eds.) Research advances irt alcohol 
and drug problems (Vol.3, pp. 49-176). New York: Wiley and Sons.
Gilbert, RM . (1984). The methylxanthine beverages and foods: chemistry,
New York: Alan R. Liss.
Giles, D., & MacLaren, D. (1984). Effects o f caffeine and glucose ingestion on 
metabolic and respiratory functions during prolonged exercise. Journal o f Sports
Goldberg, A.L., & Singer, J.J. (1969). Evidence for cyclic AMP in neuromuscular 
transmission. Proceedings of the National Academy o f Sciences o f the United States of 
America, 64, 134-41.
Graham, D M. (1978). Caffeine: Its identity, dietary sources, intake, and 
biological effects. Nutrition Review, 36,97-102.
Graham T. E., & Spriet L. L. (1991). Performance and metabolic responses to a 
high caffeine dose during prolonged exercise. Journal o f Applied Physiology, 71,2292- 
2298.
Graham, T.E., Rush, J.W.E., & VanSoeren, M.H. (1994). Caffeine and exercise: 
metabolism and performance. Canadian Journal o f  Applied Sports Science, 2, 111-138.
Graham, T.E., &  Spriet, L.L. (1995). Metabolic, catecholamine, and exercise 
performance responses to various doses of caffeine. Journal o f Applied Physiology, 78, 
867-874.
Graham, T.E., Hibbert, E., & Sathasivam, P. (1995). Caffeine vs. coffee: coffee 
isn’t an effective ergogenic aid. Medicine and Science in Sports and Exercise, 27, S224. 
(Abstract).
Green, H.J., Symon, S., & Daley, R. (1990). Attenuation of human quadriceps
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
60
Greenhaff, P.L., Ren, J., Soderlund, K., & Hultman, E. (1991). Energy 
metabolism in single human muscle fibers during contraction without and with 
epinephrine infusion. American Journal o f  Physiology, 260, E713-E718.
Gronert, G.A. (1980). Malignant hyperthermia. Anesthesiology, 53, 395-423.
Hofinann, W. (1969). Caffeine effects on transmitter depletion and mobilization at 
motor nerve terminals. American Journal ofPhysiology, 216, 621-29.
Horst, K., & Jenkins, W. (1935). The effect o f caffeine, coffee and decaffeinated 
coffee upon blood pressure, pulse rate and sample reaction time of men of various ages. 
Journal o f Pharmacology and Experimental Therapeutics,.53,385-398.
Jackman, M., Wendling, P., Friars, D., & Graham, T.(1996). Metabolic, 
catecholamine and endurance responses to caffeine during intense exercise. Journal of 
Applied Physiology, .81, 1658-63.
Jacobson, B.H., & Edgley, BM.(1987). Effects of caffeine on simple reaction 
time and movement time. Aviation, Space and Environmental Medicine, 58, 1153-56.
Jacobson, BTI., & Edgley, BM.(1990). Effects o f ingested doses of caffiene on 
neuromuscluar relex response time in man. International Journal o f Sports Medicine, 11, 
194-97.
James, J.E. (1991). Caffeine and Health. San Diego: Academic Press, Inc.
Kjaer, M., Bangsbo, J., Lortie, G., & Galbo, H. (1988). Hormonal response to 
exercise in man: Influence o f  hypoxia and physical training. American Journal o f 
Physiology, 254, R197-R203.
Lieberman, H R., Wurtman, R.J., Emde, G.G., Roberts, C., & Coviella, I.L.G. 
(1987). The effects o f low doses of caffiene on human performance and mood.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
61
2,308-312.
Lopes, J.M., Aubier, M., Jardin, J., Aranda, J.V., & Macklem, P.T. (1983). Effect 
o f caffeine on skeletal muscle function before and after fatigue. Journal o f Applied 
Physiology, 54, 1303-1305.
Marieb E. M. (1992). Human Anatomy and Physiology (2nd ed ). Redwood City: 
Benjaniin/Cuinmîngs Publishing Company, Inc.
Mitsumoto, H., Deboer, G.E., Bimge, G., Andrish, J.T., Tetzlaff, J.E., & Cruse, 
R.P. (1990). Fiber-type specific caffeine sensitivities in normal human skinned muscle 
fibers. Anesthesiology, 72, 50-54.
Moritani, T. (1992). Time course o f adaptations during strength and power 
training. In P.V. Komi, Strength and Power in Sport (pp. 266-278). Cambridge, MA: 
Blackwell Scientific Publications.
Mullin, F.J., Kleitman, N., & Cooperman, N.R. (1933). Studies of the physiology 
of sleep. X. The effect of alcohol and caffein (sic) on motility and body temperature 
during sleep. American Journal of Physiology, 106, 478-487.
Nehlig, A., & Debry, G (1994). Caffeine and sports activity: a review. 
International Journal of Sports Medicine, IS, 215-223.
Nevill, M E., Boobis, L.H., Brooks, S., & Williams, C. (1989). Effect o f training 
on muscle metabolism during treadmill sprinting. Journal o f Applied Physiology, 67, 
2376-2382.
Noakes, T. (1991). I^re  of running (3rd ed.). Champaign, IL: Leisure Press.
Parsons, W.D., Neims, MJ3. (1978). Effect o f  smoking on caffeine clearance. 
Clinical Paimacoiogy and Therapeutics, 24,40-45.
Poledna, J., & Morad, M. (1983). Effects o f caffeine on the birefringence signal in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
62
single skeletal muscle fibers and mammalian heart. PfluegersArchiv. European Journal 
ofPhysiology, 397,184-189.
Powers, S.K., Byrd, R.J., Tulley, R., & Callender, T. (1983). Effects o f caffeine 
ingestion on metabolism and performance during graded exercise. European Journal of 
Applied Physiology, 50, 301-307.
Powers, S.K., & Dodd, S. (1985). Caffeine and endurance performance. Sports. 
Medicine, 2,165-174.
Rail, T.W. (1980). Central nervous system stimulants; in Gilman et al. (Eds) The 
Pharmacological Basis o f  Therapeutics (pp. 592-607). New York: MacMillan.
Rail, T.W. (1985). Pharmacological basis o f therapeutics (7th ed.). New York: 
Macmillan.
Ramadoss, C.S., Uyeda, K., & Johnson, J.M. (1976). Studies on the fatty acid 
inactivation of phosphofructokinase. Journal o f Biological Chemistry, 251, 98-107.
Rapoport,J.L., Jensvold, M., Elkins, R., Buchsbaum, M.S., Weingartner, H., 
Ludlow, C., Zahn, T., Berg, C.J., & Neims, A.H. (1981). Behavioral and cognitive effects 
of caffeine in boys and adults. Journal o f Nervous and Mental Disorders, 169, 726-732.
Ravussin, E., Bogardus, C., Scheidegger, K., LaGrange, B., Horton, E., & Horton, 
E. (1986). Effect o f elevated FFA on carbohydrate and lipid oxidation during prolonged 
exercise in humans. Journal o f Applied Physiology, 893-900.
Roache, JT)., & Griffiths, R.R. (1987). Interactions o f  diazepam and caffeine: 
Behavioral and subjective dose effects in humans. Pharmacology, Biochemistry and 
Behavior, 26, 801-812.
Robertson, D., Wade, D., Workman, R., Woosley, R.L., & Oates J.A. (1981). 
Tolerance to the humoral and hemodynamic effects o f caffeine in man. Journal of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
63
Mill-1117.
Routh, J., Shane, N., Arredondo, E., & Paul, W. (1969). Determination o f 
caffeine in serum and urine. Clinical. Chemistry, 15,661-668.
Sant’Ambrogio, G., Frazier, D.T., & Boyarski, L.L., (1962). Effect of caffeine on 
spinal reflexes. Proceedings o f  the Society for Experimental Biology and Medicine, 109, 
273-76.
Sharp, R.L., Costill, D.L., Fink, W.J., King, D.S. (1986). Effects of eight weeks of 
bicycle ergometer sprint training on human muscle buffer capacity. International Journal 
of Sports Medicine,7, 13-17.
Somani, S.M., Khana, N.N., & Bada, H.S. (1980). Caffeine and Theophylline: 
Serum/CSF correlation in premature infants. Journal ofPediatrics,_96, 1091-1093.
Spriet L.L., MacLean D.A., Dyck D.J., Hultman E., Cederblad G., & Graham T.E. 
(1992). Caffeine ingestion and muscle metabolism during prolonged exercise in humans. 
American Joiunal ofPhysiology, 262, E891-E898.
Spriet, L.L., (1995). Caffeine and Performance. International Journal o f Sport 
Nutrition, 5, S84-S99.
Stamford, B. (1989). Caffeine and Athletes. Physician Sports Medicine, 17, 193-
194.
Sutherland, E.W., & Rail, T.W., (1958). Fractionation and characterization of a 
cyclic adenine ribonucleotide formed by tissue particles. Journal o f Biological Chemistry_ 
232,1077-1091.
Sutherland, E.W., Robison, A., & Butcher, R.W. (1968). Some aspects of the 
biological role of adenosine 3',5-monophosphate (cyclic AMP). Circulation, 37, 279-306. 
Tamopolsky, M.A., Atkinson, S.A., MacDougall, J.D., Sale, D.G., & Sutton, J R.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
64
(1989). Physiological responses to caffeine during endurance running in habitual caffeine 
users. Medicine and Science in Sports and Exercise, 31, 418-24.
Toner, M.M., Kirkendall, D.T., Delio, D J ., Chase, J.M., Cleary, P.A., & Fox,
E.L. (1982). Metabolic and cardiovascular responses to exercise with caffeine.
Trice, I., Haymes, E.M. (1995). Effects o f caffeine ingestion on exercise-induced 
changes during high-intensity, intermittent exercise. International Journal o f Sport
van Calker, D., Muller, M., & Hamprecht, B. (1979). Adenosine regulates via two 
different types of receptors: The accumulation o f cyclic AMP in cultured brain cells. 
Journal of Neurochemistry, 33, 999-1005.
Van Soeren, M Jï., Sathasivam, P., Spriet, L.L., & Graham, T.E. (1993). Caffeine 
metabolism and epinephrine responses during exercise in users and nonusers. Journal of
Van Soren, M.H., Molr, T., Kjaer, M., Graham, T.E. (1996). Acute effects of 
caffeine ingestion at rest in humans with impaired epinephrine responses. Journal of 
Applied Physiology, &0,999-1005.
Weir, J., Noakes, T.D., Myburgh, K., & Adams, B. (1987). A high carbohydrate 
diet negates the metabolic effect of caffeine during exercise. Medicine and Science in
Wiles, J.D., Bird, S.R., Hopkins, J., Riley, M. (1992). Effect o f caffeinated coffee 
on running speed, respiratory factors, blood lactate and perceived exertion during 1 SOO-m 
treadmill running. British Journal of Sports Medicine, 26, 116-120.
Williams, M. (1987). Purine receptors in mammalian tissues: pharmacology and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
65
functional significance. Annual Review o f Pharmacology and Toxicology, 27, 315-45.
Williams, JJ i., Signorile, J.F., Barnes, W.S., Henrich, T.W. (1988). Caffeine, 
maximal power output and fatigue. British Journal o f Sports Medicine, 22, 132-134.
Williams, J. (1991). Caffeine, neuromuscular function and high-intensity exercise 
performance. Journal o f  Sports Medicine and Physical Fitness, 31,481-489.
Yesair, D.W., Branfinan, A.R., & Callahan, M M . (1984). Human disposition and 
some biochemical aspects of methylxantbines. In GA Spiller (ed.). The methylxanthine 
beverages and foods:Chemistry, consumption, and health effects (pp. 215-234). New 
York: Alan R. Liss.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
